Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox plus deferoxamine followed by deferasirox monotherapy in adults with beta-thalassemia and severe cardiac iron overload
2009-018091-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox and deferoxamine in beta thalassemia and iron overload, sponsored by Novartis. Primary endpoints: Primary efficacy endpoint and Safety and tolerability. Started Nov 2010; status: completed.
02
Drugs
deferasiroxdeferoxamine
03
Conditions
beta thalassemiairon overload
Beyond the preview
Go deeper on 2009-018091-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018091-34.